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A severe case of warfarin–canrenoate interaction: a role for
genetic predisposition?
The interindividual variability in warfarin response is generally
attributed to dietary vitamin K intake, drug interactions,
demographic and genetic factors (D’Andrea et al, 2008). Many
drugs are known to modify international normalized ratio
(INR) values in warfarin-treated patients both for pharmaco-
dynamic and pharmacokinetic interactions. We report an
unusual case of interaction between potassium canrenoate
(PC) and warfarin in a 77-year-old Caucasian female with
atrial fibrillation, heart failure (New York Heart Association
class II) and hypertension. During the previous 5 years, the
patient had been effectively anticoagulated with warfarin
35Æ0 mg/week with a very stable INR (Fig 1); in the last
10 months drug therapy also included furosemide, bisoprolol
and ramipril. Two weeks after PC addition (50 mg/d) to
control a slight hypokalaemia, she suddenly developed an
extensive facial and neck haematoma after a mild lesion of the
internal jowl, followed by analogous limb lesions as conse-
quences of mild traumas. Blood examinations revealed a
marked INR increase (10Æ8), requiring warfarin discontinua-
tion and vitamin K administration. Warfarin treatment was
suspended until INR reached 1Æ0; subsequent titrations after
warfarin reintroduction eventually resulted in a stable INR
within the therapeutic range (2Æ0–3Æ0) with a final regimen of
22Æ5 mg/week (about 66% of the previous dose); PC was never
withdrawn. Any other possible factor able to interfere with
warfarin therapy was excluded, including: recent illness,
changes in dietary vitamin K intake, over-the-counter prod-
ucts, fruit-juices, herbal products, alcohol, tobacco. The
patient and her relatives confirmed adherence to drug therapy.
Warfarin inhibits the synthesis of vitamin K-dependent
clotting factors via inhibition of the vitamin K epoxide
reductase complex 1 (vkorc1) and is primarily metabolized
via cytochrome P450 2C9 (cyp2c9). The patient was genotyp-
ized for three warfarin-related SNPs, CYP2C9*2, CYP2C9*3
and VKORC1 -1639G>A (rs9923231, minor allele frequency
0Æ432 in Caucasian population) (D’Andrea et al, 2008). The
Taqman Drug Metabolism Genotyping Assay (Applied Bio-
systems, Foster City, CA) was used. The patient was found to
be homozygous wild-type for both CYP2C9 loci and homo-
zygous -1639AA (low dose required) for VKORC1. Both PC
and warfarin are highly bound to human serum albumin
(HSA), and PC was previously shown to competitively displace
warfarin from HSA to a significantly higher extent than
spironolactone (the latter was, on the contrary, reported to
decrease the anticoagulant effect of warfarin by means of
clotting factors concentration) (O’Reilly, 1980; Takamura et al,
1997). This interaction may increase warfarin bioavailability,
taking also into account that both R-Warfarin and PC undergo
extensive hepatic metabolism via CYP3A (Cook et al, 1993;
D’Andrea et al, 2008).
To date, this is the first clinically relevant interaction
between warfarin and PC. Its imputability was graded as
‘probable’ according to the objective causality assessment
performed by our Pharmacovigilance Unit. As the combina-
tion of warfarin and PC might be quite common in
cardiovascular therapy (e.g. 2042 out of 58 831 – 3Æ5% –
warfarin users have at least a coexistent prescription of PC
within a time window of 1–3 months according to recent
prescription data of Tuscany), we hypothesize that the increase
in warfarin serum concentration afforded by PC pharmacoki-
netic interactions may lead to a clinically relevant bleeding
syndrome only in subjects with a warfarin-sensitive genotype
(e.g. VKORC1 -1639AA as in the present case).
(A)
(B)
Fig 1. Clinical manifestations of the patient. (A) Patient’s lesions.
(B) Patient’s INR.
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Paroxysmal nocturnal haemoglobinuria clones in children with
acquired aplastic anaemia: a prospective single centre study
Previous studies in adults with acquired aplastic anaemia (AA)
found a high incidence of paroxysmal nocturnal haemoglo-
binuria (PNH) minor clones at diagnosis, associated with a
better response to immunosuppressive therapy (IST) (Macie-
jewski et al, 2001; Ishiyama et al, 2003; Sugimori et al, 2006).
Few studies exist regarding the origin and changes over time of
PNH clones in children with AA. In a previous study (Timeus
et al, 2005) the simultaneous flow cytometric analysis (FCA) of
circulating CD34+ cell absolute count and apoptotic rate (AR)
in children with AA identified a typical pattern at diagnosis or
relapse (low CD34+ count and high AR) and at myelodysplas-
tic transformation (high CD34+ count and low AR). The
present study aimed to assess the incidence of PNH+ cells in
AA children at diagnosis, during IST and off-therapy, and to
evaluate its correlation with the functional state of circulating
CD34+ cells, response to IST and survival.
A cohort of 24 Caucasian children (median age 8Æ7 years, 14
males and 10 females) with AA diagnosed between 1990 and
2009 (18 severe or very severe and six non severe AA, according
to Camitta et al (1976) criteria), was prospectively studied for
the presence of PNH+ cells by FCA, since 1998. All but four
patients (Patients 5, 7, 14 and 16, Fig 1), who received related
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